January 16, 2026 Chantal Thurlby-Alexander 4 min read PADCEV + Keytruda improve survival in muscle-invasive bladder cancer GeneralLatest NewsOncologyProduct NewsPublic HealthUrology PADCEV (enfortumab vedotin) plus Keytruda has demonstrated significant improvements in event-free and overall survival in patients with muscle-invasive bladder cancer, regardless of cisplatin eligibility. Read more
